PETALING JAYA: Following its upliftment from Practice Note 17 in March, Pharmaniaga Bhd
is staying focused on strengthening its operational processes to enhance its product portfolio and delivering quality healthcare solutions.
Releasing its results for the second quarter ended June 30, 2026 (2Q26) for the fiscal year ending 2026 (FY26) yesterday, Pharmaniaga saw net profit more than triple year-on-year (y-o-y) to RM12.5mil, as revenue also climbed 12.3% to RM1.04bil.
The group credited 2Q26 top line growth primarily to the higher-volume order from government hospitals under the Approved Products Purchase List and increased sales from the private segment.
It also attributed realised interest savings of RM7mil following the partial repayment of borrowings, supported by effective inventory management to the better profitability.
For the six months ended June, Pharmaniaga saw the bottom line increase by 31.1% y-o-y to RM44mil, as turnover grew 12% to RM2.2bil.It said revenue growth was primarily driven by heightened customer demand in the concession segment, while a realised interest saving of RM14.2mil following the partial repayment of borrowings through proceeds from the Regularisation Plan, supported by effective inventory management, also contributed to the rise in net profit.
Compared to 1Q26 however, net profit fell 60% from RM31.5mil, coinciding with a slide in revenue from RM1.2bil.
Pharmaniaga said the softer quarter-on-quarter performance was mainly due to lower contributions from its concession business, attributed to higher government hospital purchases in 1Q26, following budget disbursement early in the year.
The group proposed a dividend of 0.48 sen per share for 2Q26, bringing total dividends declared for FY26 to 1.73 sen per share.
Moving forward, it said its focus remains on executing its strategic priorities under Vision ONE30 by accelerating the commercialisation of its biopharmaceutical portfolio, strengthening its pharmaceutical and logistics businesses, and expanding its regional footprint.
